ASPR/BARDA - EverGlade Consulting
Antibodies attacking virus cell for BARDA Funding

ASPR and BARDA Funding

ASPR encourages participation from a diverse range of entities, including educational institutions, nonprofit organizations, and businesses of all sizes, particularly those with innovative solutions that can help protect the nation from CBRN threats.

The Biomedical Advanced Research and Development Authority (BARDA) provides funding opportunities aimed at developing and procuring necessary medical countermeasures, such as vaccines, therapeutics, and diagnostics, for public health emergencies.  Using Broad Agency Announcements (BAAs/EZ-BAAs), Requests for Proposals, and Other Transaction Agreements, ASPR engages industry through a variety of funding opportunities.

ASPR MCM & Biodefense Opportunities

ASPR’s MCM portfolio includes programs such as DRIVe, CARB-X, Project NextGen, IBx, and the Strategic National Stockpile.

Rapid Response Partnership Vehicle (RRPV)

Facilitates public-private partnerships to rapidly develop medical countermeasures in preparation for and during health emergencies.

Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C)

Advances biomanufacturing innovations to enhance production efficiency and scalability.

BARDA Alliance Network

Strengthens collaborations to expedite the delivery of vaccines, therapeutics, and diagnostics.

BARDA TechWatch

Present your novel technology, product, or capability to BARDA and receive direct feedback on interest & alignment.

Contact Us

Scroll to Top
A yellow lab flask with Donald Trump hair and a red tie.

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.

Sign Up